Pacific Biosciences of California, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PACB research report →
Range $1.35 – $2.5
Price Chart
About the company
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions.
- CEO
- Mark Van Oene
- IPO
- 2010
- Employees
- 485
- HQ
- Menlo Park, CA, US
Get TickerSpark's AI analysis on PACB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $508.95M
- P/E
- -4.01
- PEG
- -0.06
- P/S
- 3.26
- P/B
- -8.54
- EV/EBITDA
- -10.39
- Div Yield
- 0.00%
- Gross Margin
- 34.51%
- Op Margin
- -99.59%
- Net Margin
- -81.31%
- ROE
- 604.22%
- ROIC
- -24.48%
Latest fiscal year · YoY change
- Revenue
- $160.00M+3.9%
- Gross Profit
- $50.67M+35.9%
- Op Income
- $-557,561,000
- Net Income
- $-546,376,000-76.3%
- EPS
- $-1.82-61.1%
- OCF Growth
- +46.0%
- FCF Growth
- +46.3%
- 52W High
- $3.44
- 52W Low
- $1.07
- 50D MA
- $2.05
- 200D MA
- $1.60
- Beta
- 2.20
- RSI (14)
- 38
- Avg Volume
- 13.12M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
PacBio posted modest Q3 revenue growth, improved commercial traction for SPRQ-Nx, and reaffirmed a path to lower cash burn and 2028 breakeven, while acknowledging continued funding pressure in some end markets.· November 4, 2026
- Q3 revenue was $40.6 million, up 6% year over year, with growth coming from stronger instrument sales and sequential consumables improvement.
- Non-GAAP gross margin was 36%, down from 42% a year ago, mainly due to higher memory costs and Vega manufacturing transition costs.
- SPRQ-Nx adoption continued to ramp: over half of Revio consumable revenue came from SPRQ-Nx users, and about two-thirds of the Revio installed base had upgraded software by quarter end.
- Management said clinical sequencing remains the key growth driver, with consumable business growing over 20% year over year in clinical and now exceeding 20% of overall business.
- Full-year revenue guidance was narrowed to $155 million to $160 million, while operating expense guidance was reduced on restructuring savings and cash burn is expected to step down in Q4 and 2027.
PacBio reported third-quarter 2026 revenue of $40.6 million, up from $38.4 million in Q3 2025. Instrument revenue was $13.2 million versus $11.3 million a year ago, consumables revenue was $20.8 million versus $21.3 million, and service/other revenue was $6.6 million versus $5.8 million. Non-GAAP gross profit was $14.6 million with gross margin of 36%, compared with $16.2 million and 42% in the prior-year quarter. Non-GAAP operating expenses were $47 million, down 13% year over year, and non-GAAP net loss was $32.8 million, or $0.11 per share, versus $36.8 million, or $0.12 per share, last year. For the full year, management narrowed revenue guidance to $155 million to $160 million, kept non-GAAP gross margin guidance at 35% to 37%, cut non-GAAP operating expense guidance to $203 million to $207 million, and expects year-end cash of about $175 million to $185 million.
Mark Van Oene emphasized that SPRQ-Nx is driving higher utilization, better economics, and broader customer adoption, with the company seeing strategic deals in clinical genomics, national research, and bioAI. He framed the quarter as evidence that PacBio is becoming infrastructure for larger genomic programs and AI-enabled discovery, citing GeneDx, Berry Genomics, Verily, TychoBio, and Basecamp as examples. His tone was upbeat and confident, but he repeatedly noted that the transformation will take time to translate into meaningful revenue and cash generation.
Bill Meyer highlighted the main financial drivers behind the quarter: total revenue of $40.6 million, gross margin of 36%, and a non-GAAP net loss of $32.8 million. He pointed to higher memory costs and Vega manufacturing transition costs as the main reasons gross margin fell year over year, while operating expenses declined to $47 million due to expense discipline and lower share-based compensation. He also laid out the updated outlook: revenue of $155 million to $160 million, gross margin of 35% to 37%, operating expenses of $203 million to $207 million, year-end cash of $175 million to $185 million, and a plan for cash burn to fall meaningfully in 2027 as restructuring savings and reduced high-throughput development spending take hold.
Analysts focused on clinical growth, cash burn, debt, SPRQ-Nx monetization, the high-throughput platform, and regional demand trends. Management said the clinical consumables business is growing over 20% year over year and now exceeds 20% of total business, while confirming that Q4 cash burn should be lower because Q3 included working-capital timing effects. On debt, they said there is no immediate need to address the 2029 and 2030 convertibles prematurely. On the high-throughput platform, Mark said development remains on track for a commercial launch by the end of next year. In Europe, management said clinical is the fastest-growing segment and in Singapore they still expect a possible long-read component in the remaining PRECISE work despite Illumina and Ultima winning the first awarded portion.
The positive case from this call is that SPRQ-Nx appears to be gaining real traction, with higher utilization, reorders beginning, and management expecting most of the installed base to opt in by year-end. Clinical sequencing is showing strong growth, and PacBio is landing visible programs with GeneDx, Berry Genomics, Sampled, Verily, and TychoBio that could expand long-term pull-through. Management also believes the high-throughput platform remains on track, which could support larger projects and improve economics further in 2027 and beyond.
The main risks remain weak academic and government funding, especially in the Americas, and uneven capital spending trends that management said are still constraining instrument demand. Gross margin fell sharply year over year to 36% because of higher memory costs and Vega manufacturing transition costs, and consumables are still working through inventory and workflow transitions. The company also acknowledged that revenue gains from the new deals will take time to convert into meaningful revenue and cash generation, while cash remains limited at about $199.4 million at quarter end.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.1%
- Shares Outstanding
- 312.24M
- Float Shares
- 306.23M
of shares held by institutions
229 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 32.34M | ▲ 7.07M |
| Ark Investment Management LLC | 29.78M | ▼ 6.49M |
| Softbank Group Corp. | 20.45M | 0 |
| Vanguard Group Inc | 17.04M | ▲ 657.34K |
| Vanguard Capital Management LLC | 13.40M | ▲ 620.49K |
| Geode Capital Management, LLC | 6.63M | ▼ 972.08K |
| State Street Corp | 6.05M | ▲ 89.38K |
| Amova Asset Management Americas, Inc. | 6.01M | ▼ 1.03M |
| Sumitomo Mitsui Trust Group, Inc. | 4.96M | ▼ 1.05M |
| Point72 Asset Management, L.P. | 4.79M | ▲ 4.50M |
| Two Sigma Investments, LP | 4.24M | ▲ 732.99K |
| D. E. Shaw & Co., Inc. | 4.21M | ▲ 570.60K |
Held by 206 ETFs
Biggest fund positions in PACB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | MEYER WILLIAM | other | 54,945 |
| Nov 17, 26 | MEYER WILLIAM | other | 72,309 |
| Nov 17, 26 | ORDONEZ KATHY | sell | 18,595 |
| Nov 3, 26 | MEYER WILLIAM | other | 0 |
| Oct 6, 26 | Gibson James R II | other | 500,000 |
| Oct 6, 26 | Gibson James R II | other | 500,000 |
| Oct 6, 26 | Gibson James R II | sell | 661,815 |
| Aug 17, 26 | Van Oene Mark | sell | 26,911 |
| Aug 10, 26 | Van Oene Mark | other | 489,130 |
| Aug 10, 26 | Van Oene Mark | other | 1,967,888 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PACB coverage
Recent articles, reports, and earnings notes.
No research on PACB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PACB report →PacBio to Participate in the Piper Sandler 38th Annual Healthcare Conference
globenewswire.com · Nov 17
Here's Why Pacific Biosciences (PACB) Is a Great 'Buy the Bottom' Stock Now
zacks.com · Nov 16
Pacific Biosciences Q3: Another Revenue Guidance Cut
seekingalpha.com · Nov 5
Pacific Biosciences of California, Inc. (PACB) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Pacific Biosciences of California (PACB) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 4
What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call
marketbeat.com · Nov 4
PacBio Announces Third Quarter 2026 Financial Results
globenewswire.com · Nov 4
Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts
zacks.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.